The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified. A modified chemotherapy regimen consisting of docetaxel, folinic acid ...
Use of gene set analysis (GSA) for molecular classification of responders and nonresponders to FOLFOX therapy in colorectal cancer (CRC). This is an ASCO Meeting Abstract from the 2012 ASCO Annual ...
The authors say delivering FOLFOX via transarterial infusion could be a “perfect option for treating intrahepatic cholangiocarcinoma before patients receive targeted therapy, immunotherapy, or ...
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (CPT-11 + oxaliplatin [IRINOX]) and two standard arms (LV5-FU2 + CPT-11 [FOLFIRI], LV5-FU2 + ...
Please provide your email address to receive an email when new articles are posted on . The PROSPECT trial showed FOLFOX to be noninferior to pelvic chemoradiation before surgery with regard to DFS.
Young women with gastrointestinal cancers who received the FOLFIRI or FOLFOX chemotherapy regimens experienced a benefit in terms of reduced nausea and vomiting with the combination of aprepitant plus ...
Aprepitant, palonosetron and dexamethasone curbed chemotherapy-induced nausea and vomiting in certain women with gastrointestinal cancers who were receiving FOLFIRI or FOLFOX regimens. A combination ...
Yakult Honsha has patented a method for predicting the effectiveness of FOLFOX or FOLFIRI regimens in treating stage IV colorectal cancer. By measuring copy number gains in specific chromosome regions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results